Biocon to scale up investments in small molecules business
Biocon Ltd plans to scale up investment in its small and complex drug molecules vertical over the coming years using proceeds from a proposed initial public offering of its biologics operations, said a senior company official. This will mark a shift in Biocon’s strategy as the company had tapped capital from its small molecules operations over the past decade to fund growth of its then-fledgling biologics business, Siddharth Mittal, chief executive and joint managing director of Biocon said in an interview. He said the firm plans to invest a part…
Read More